This filing details transactions made by Saathoff MardiLyn, General Counsel, Chief Compliance Officer, and Senior Vice President of Regulatory Affairs at Northwest Natural Holding Co. On December 22, 2025, MardiLyn Saathoff disposed of a total of 1.1235 shares of Common Stock at a price of $46.90 per share. These dispo...

This filing details a transaction by James Richard Porter, President and CEO of Nuvalent, Inc. On December 19, 2025, Porter acquired 57,000 shares of Class A Common Stock under a stock option, with the shares underlying the option being fully vested. The exercise price for these shares was $0.65 per share. Following th...

This filing details a Form 4 submission by Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. On December 22, 2025, Mr. Pelish exercised a stock option to acquire 5,085 shares of Class A Common Stock at an exercise price of $1.08 per share. This transaction is marked as a derivative disposition ('D') with a ma...

Raymond F. O'Conor, a director at ARROW FINANCIAL CORP, reported transactions on December 19, 2025. He acquired 1093 shares of Common Stock through the exercise of a Director Stock Option at a price of $27.04 per share. This option, which vested in four equal annual installments starting January 27, 2022, had an exerci...

This filing details a transaction by Andrea O'Donnell, EVP & Brands President of Designer Brands Inc. The transaction, dated December 19, 2025, involves 2,180 Dividend Equivalent Rights, which are economically equivalent to Class A Common Shares. These rights accrued on previously awarded restricted stock units (RSUs) ...

William O'Dowd IV, Chief Executive Officer and Director of Dolphin Entertainment, Inc. (DLPN), reported a purchase of 3,300 shares of common stock on December 22, 2025. The purchase was made at a weighted average price of $1.502 per share, with individual transactions ranging from $1.46 to $1.52. Following this transac...

This filing details transactions by Christian G. O'Neil, President and COO of KIRBY CORP. On December 22, 2025, O'Neil acquired 11,145 shares of Common Stock through the exercise of employee stock options at a price of $73.29 per share, increasing his post-transaction holdings to 25,980 shares. Concurrently, he dispose...

Vincent James O'Neill, Chief Financial Officer of Iridium Communications Inc., reported a transaction on December 19, 2025. The transaction involved the disposal of 1304 shares of Common Stock at a price of $17.04 per share, for a total value of $22,221.60. This transaction was executed under transaction code "F", indi...

On December 19, 2025, Adeoye Y Olukotun, a director at Arrowhead Pharmaceuticals, Inc. (ARWR), sold a total of 10,000 shares of common stock. These sales were executed under a Rule 10b5-1 trading plan. The transactions included 3,090 shares at a weighted average price of $66.70, 6,083 shares at a weighted average price...

Naomi O. Seligman, a director at Oracle Corp (ORCL), reported a disposition of 2,223 shares of Common Stock on December 23, 2025. The shares were sold at a price of $196.61 per share. Following this transaction, Ms. Seligman has 25,596 shares remaining. Her holdings also include 6,000 shares held by her spouse and 14,4...

Oregon Community Foundation, a ten percent owner, reported the disposition of 1000 shares of Common Stock on December 19, 2025, at a price of $2.2545 per share. This transaction resulted in 873,847 shares held directly. Subsequently, on December 22, 2025, the foundation disposed of an additional 859 shares of Common St...

George C. Roeth, a director at Oil-Dri Corp of America (ODC), reported a gift of 2,000 shares of Common Stock on December 23, 2025. The transaction code was "G", indicating a gift, and the shares were disposed of ("D") with a transaction price of $0.00. Following this transaction, Mr. Roeth now holds 1,000 shares direc...

Okupe Oluyemi, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported a sale of 23,090 shares of Class A Common Stock on December 22, 2025. The shares were sold at an average weighted price of $35.7172, with prices ranging from $35.36 to $35.88. This transaction was executed as part of a Rule 10b5-1 tradi...

This filing details stock transactions by Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals, Inc. On December 19, 2025, Zojwalla acquired 40,000 shares of common stock at $15.25 per share and disposed of 57,079 shares at an average price of $28.03 and 12,921 shares at an average price of $28.93. Further t...

Javier Olivan, Chief Operating Officer of Meta Platforms, Inc., reported the sale of 517 shares of Class A Common Stock on December 22, 2025, under a Rule 10b5-1 trading plan. The transaction occurred at a price of $661.11 per share, resulting in a post-transaction share ownership of 12,717 shares. The filing also deta...

This filing details a transaction by Nicholas A. Saccomano, President and CEO of OnKure Therapeutics, Inc. On December 22, 2025, Mr. Saccomano disposed of 87 shares of Class A Common Stock at a weighted average price of $2.9677 per share. These shares were automatically sold to cover tax withholding obligations related...

On December 22, 2025, Randy Seidl, a director at Ondas Holdings Inc. (ONDS), reported several transactions involving Common Stock and Restricted Stock Units (RSUs). These transactions included the acquisition of shares upon the vesting of RSUs, with no cost basis, as indicated by a transaction price of 0.0. Concurrentl...

On December 22, 2025, Jaspreet Sood, a director at Ondas Holdings Inc. (ONDS), reported several transactions involving Common Stock and Restricted Stock Units (RSUs). Sood acquired shares through the vesting of RSUs, with 21,034 shares acquired from the vesting of RSUs granted on November 18, 2024, and 19,608 shares fr...

Edward Stelmakh, Chief Finance & Strat Officer at OptimizeRx Corp, reported a disposition of 3,658 common shares on December 23, 2025. The shares were withheld by the issuer to cover tax obligations upon the vesting of restricted stock units. The transaction price was $12.74 per share, and Mr. Stelmakh now owns 123,172...

Stephen L. Silvestro, Chief Executive Officer of OptimizeRx Corp, reported a disposition of 3,361 shares of Common Stock on December 23, 2025. The shares were sold at a price of $12.74 per share, totaling $42,844.74. This transaction was conducted under a Rule 10b5-1(c) plan adopted on March 11, 2021. Following this di...

This Form 4 filing reports a transaction by insider Ted L. Tewksbury III on December 19, 2025. Mr. Tewksbury, a director at Ouster, Inc., sold 1,695 shares of Common Stock at a price of $21.47 per share. This sale was conducted under a Rule 10b5-1 trading plan established on August 12, 2025, and included shares sold fo...

David Owens, Chief Medical Officer and Director of Nexalin Technology, Inc., was granted 1,000,000 stock options on December 19, 2025. These options were granted under the 2023 Equity Incentive Plan, pending shareholder approval to increase the plan limit per NASDAQ rules. The options have an exercise price of $0.83 an...

This Form 4 filing reports that Leon Trefler, Chief of Clients and Markets at Pegasystems Inc., received 620 shares of common stock on December 19, 2025, through a gift transaction (Transaction Code G). The shares were acquired at $0 per share, indicating they were likely granted as compensation or through a company be...

This Form 4 filing details a transaction by Benjamin I. Zachary, a director at PEOPLES BANCORP OF NORTH CAROLINA INC. On December 22, 2025, Mr. Zachary acquired 121 shares of Common Stock at a price of $34.14 per share, as part of a 30-year service award. Following this transaction, his total ownership of Common Stock ...

This filing details significant transactions by Perceptive Advisors LLC and its affiliated entities concerning Athira Pharma, Inc. (ATHA). On December 23, 2025, these entities acquired a substantial number of securities, including common stock and various warrants (Pre-Funded, Series A, and Series B). The transactions ...